Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:30 AM EDTCompany ParticipantsRyan Cohlhepp - ...

Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC). Background: To analyze post-neoadjuvant molecular events ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

Bicara Therapeutics (NASDAQ:BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

Sangamo Therapeutics has initiated a rolling Biologics License Application (BLA) submission with the U.S. Food and Drug Administration for its investigational g ...

BAY-876是一种高选择性葡萄糖转运蛋白1（GLUT1）抑制剂，通过靶向抑制GLUT1介导的葡萄糖摄取，在多种研究中展现出显著的代谢调控与抗增殖作用。其作用机制主要包括：（1）直接抑制GLUT1蛋白表达，如Western ...

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...

Y-complex nucleoporin, Nup107, can regulate ecdysone production by affecting the transcription of Halloween genes and levels of RTK receptor, torso, for the metamorphic transition from larva to pupa.

Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA ...

Roche Holding AG ( RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline March 9, 2026 12:00 PM EDT ...